EUTOS Score (CML Prognosis on Imatinib)
EUTOS Score (CML Prognosis on Imatinib) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the EUTOS Score (CML Prognosis on Imatinib) → Runs in your browser. No signup, no tracking.
What this is
EUTOS Score (CML Prognosis on Imatinib) is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. EUTOS Score (CML Prognosis on Imatinib) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686-692. Read the source ↗
Worked example: EUTOS 104 — high risk (> 87): lower 18-month complete-cytogenetic-response and progression-free-survival rates.
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.